Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation

被引:76
|
作者
Adkins, Farrell C. [1 ]
Gonzalez-Angulo, Ana Maria [2 ]
Lei, Xiudong [3 ]
Hernandez-Aya, Leonel F. [2 ]
Mittendorf, Elizabeth A. [1 ]
Litton, Jennifer K. [2 ]
Wagner, Jamie [1 ]
Hunt, Kelly K. [1 ]
Woodward, Wendy A. [4 ]
Meric-Bernstam, Funda [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
COMPARING TOTAL MASTECTOMY; 20-YEAR FOLLOW-UP; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; PREMENOPAUSAL WOMEN; CONSERVING SURGERY; RADIOTHERAPY; PHENOTYPE; PATTERNS; THERAPY;
D O I
10.1245/s10434-011-1920-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR). The purpose of this study was to determine the impact of operation type on LRR in TNBC patients. Methods. A total of 1325 patients with TNBC who underwent breast-conserving therapy (BCT) or mastectomy from 1980 to the present were identified. Clinical and pathological factors were compared by the chi-square test. LRR-free survival (LRRFS), distant metastasis-free survival, and overall survival were estimated by the Kaplan-Meier method. Multivariate analysis was performed by the Cox proportional hazard models. Results. BCT was performed in 651 patients (49%) and mastectomy in 674 (51%). The mastectomy group had larger tumors, a higher incidence of lymphovascular invasion, and higher pathologic N stage (all P < 0.001). At 62-month median follow-up, LRR was seen in 170 (26%) in the BCT group and 203 (30%) in the mastectomy group. Five-year LRRFS rates were higher in the BCT group (76% vs. 71%, P = 0.032), as was distant metastasis-free survival (68% vs. 54%, P < 0.0001) and overall survival (74% vs. 63%, P < 0.0001). On multivariate analysis, T stage (hazard ratio [HR] 1.37, P = 0.006), high nuclear grade (HR 1.92, P = 0.002), lymphovascular invasion (HR 1.93, P < 0.0001), close/positive margins (HR 1.89, P < 0.0001), and use of non-anthracycline or taxane-based adjuvant chemotherapy (HR 2.01, P < 0.0001) increased the LRR risk, while age [ 50 years was protective (HR 0.73, P = 0.007). Operation type (mastectomy vs. BCT, HR 1.07, P = 0.55) was not statistically significant. Conclusions. BCT is not associated with increased LRR rates compared to mastectomy. TNBC should not be considered a contraindication for breast conservation.
引用
收藏
页码:3164 / 3173
页数:10
相关论文
共 50 条
  • [31] Triple-negative breast cancer in the elderly
    Shagisultanova, Elena
    Mayordomo, Jose
    Elias, Anthony D.
    BREAST JOURNAL, 2017, 23 (06): : 627 - 629
  • [32] Characteristics of triple-negative breast cancer
    Tim C. de Ruijter
    Jürgen Veeck
    Joep P. J. de Hoon
    Manon van Engeland
    Vivianne C. Tjan-Heijnen
    Journal of Cancer Research and Clinical Oncology, 2011, 137 : 183 - 192
  • [33] Male Triple-Negative Breast Cancer
    Qavi, Qasif
    Alkistawi, Firas
    Kumar, Shashi
    Ahmed, Rizwan
    Al-Zawi, Abdalla Saad Abdalla
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [34] Pharmacotherapy of triple-negative breast cancer
    Arslan, Cagatay
    Dizdar, Omer
    Altundag, Kadri
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (13) : 2081 - 2093
  • [35] An overview of triple-negative breast cancer
    Kumar, Pankaj
    Aggarwal, Rupali
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 293 (02) : 247 - 269
  • [36] Metastatic Triple-Negative Breast Cancer
    Zhang, Xiaojie
    Yeung, Kay T.
    CURRENT BREAST CANCER REPORTS, 2023, 15 (03) : 288 - 297
  • [37] Immunotherapy for Triple-Negative Breast Cancer
    Cao, Yifeng
    Chen, Chuyang
    Tao, Yi
    Lin, Weifeng
    Wang, Ping
    PHARMACEUTICS, 2021, 13 (12)
  • [38] Targeting Triple-Negative Breast Cancer
    Saljoughian, Manouchehr
    US PHARMACIST, 2020, 45 (10) : 6 - 8
  • [39] Metastatic Triple-Negative Breast Cancer
    Xiaojie Zhang
    Kay T. Yeung
    Current Breast Cancer Reports, 2023, 15 : 288 - 297
  • [40] Immunotherapy in triple-negative breast cancer
    Heather Katz
    Mohamed Alsharedi
    Medical Oncology, 2018, 35